Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon

References

• Marini C, Baldassarre M, Russo T et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. .Ai]urology62(1), 77–81 (2004).
   Google Scholar
• ••New epidemilogical data on stroke in the elderly.
   Google Scholar
• Blight A, Pereira AC, Brown MM. A single consultation cerebrovascular disease clinic is cost effective in the management of transient ischaemic attack and minor stroke. JR Coll Physicians Lon. 34(5), 452–455 (2000).
   PubMedGoogle Scholar
• Weimar C, Weber C, Wagner M et al. Management patterns and healthcare use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cembrovasc. Dis. 15(1–2), 29–36 (2003).
   Google Scholar
• Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8), 731–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart 19(1), 1–3 (1998).
   PubMedGoogle Scholar
• Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler. Thromb. Vasc. Biol. 20(4), 1052–1056 (2000).
   Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N &iguj Merl 342(12), 836–843 (2000). A classical paper on the role of C-reactive protein (CRP) in cardiovascular risk in women.
   Google Scholar
• Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32(11), 2575–2579 (2001).
   PubMed Web of Science ®Google Scholar
• ••Independent of other cardiovascular riskfactors, elevated plasma CRP levels significantly predict the risk of future ischemic stroke and transient ischemic attack in the elderly.
   Google Scholar
• van Exel E, Gussekloo J, de Craen AJ, Bootsma-van der Wiel A, Frolich M, Westendorp RG. Inflammation and stroke: the Leiden 85-Plus Study. Stroke 33(4), 1135–1138 (2002).
   Google Scholar
• ••Elderly subjects with an increased risk ofstroke had significantly higher median CRP concentrations.
   Google Scholar
• Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107(15), 2016–2020 (2003).
   PubMed Web of Science ®Google Scholar
• ••The findings suggest that elevated CRP inmiddle adulthood and in men with healthier risk-factor profiles may be important as a risk factor for TE stroke.
   Google Scholar
• Muir KW Weir CJ, Alwan W, Squire TB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stmke 30(5), 981–985 (1999).
   Google Scholar
• ••One of the first (retrospective) study onCRP in stroke patients. CRP concentration is an independent predictor of survival after ischemic stroke.
   Google Scholar
• Canova CR, Courtin C, Reinhart WH. C- reactive protein (CRP) in cerebro-vascular events. Athemsclerasis147(1), 49–53 (1999).
   PubMedGoogle Scholar
• •One of the first (prospective) study on CRP in stroke patients. CRP is not a useful marker to predict the outcome of an acute cerebrovascular event on hospital admission.
   Google Scholar
• Di Napoli M, Di Gianfilippo G, Bocola V. C-Reactive protein, serum amyloid A protein and coronary events. Circulation 100(15), 66 (1999).
   Google Scholar
• Di Napoli M, Di Gianfilippo G, Sollecito A, Bocola V. C-reactive protein and outcome after first-ever ischemic stroke. Stroke 31(1), 238–239 (2000).
   PubMedGoogle Scholar
• Di Napoli M, Papa F, Bocola V Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32(1), 133–138 (2001).
   PubMed Web of Science ®Google Scholar
• ••Increased levels of CRP within 24 h afterevent are associated with a worse outcome in patients with ischemic stroke. The increased risk associated with elevated CRP levels is independent of the prognostic influence of fibrinogen.
   Google Scholar
• Di Napoli M, Papa F, Bocola V C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32(4), 917–924 (2001). CRP is a marker of increased 1-year risk of future cardiovascular events or death in ischemic stroke. CRP at discharge is better related to later outcome and could be of greater utility for risk stratification.
   Google Scholar
• Di Napoli M, Papa F. Inflammation, hemostatic markers and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Shoke33(7), 1763–1771 (2002).
   Google Scholar
• ••Elevated levels of CRP, more than ofhemostatic markers (D-dimer and fibrinogen), are related to the risk of new cardiovascular events after ischemic stroke. The efficacy of antiplatelet therapy in secondary prevention appears to be directly related to level of inflammatory and thrombotic markers.
   Google Scholar
• Anuk T, Assayag EB, Rotstein R et al. Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol Scant/. 106(4), 196–199 (2002).
   Google Scholar
• Ceccarelli E, Donati C, Forconi S, Cappelli R, Masotti L. C-reactive protein, physical disability and prognosis in very old patients with ischemic stroke. j CerontolLi.Merl Li. 57(8), M520—M522 (2002).
   Google Scholar
• Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33(10), 2459–2464 (2002).
   PubMed Web of Science ®Google Scholar
• ••The CRP level measured within 12 h aftersymptom onset of an acute ischemic stroke is not independently related to long-term prognosis. In contrast, a CRP increase between 12 and 24 h after symptom onset predicts an unfavorable outcome and is associated with an increased incidence of cerebrovascular and cardiovascular events.
   Google Scholar
• Iyigun I, Bakirci Y. Plasma concentrations of C-reactive protein and fibrinogen in ischaemic stroke. j Int. Merl Res. 30(6), 591–596 (2002).
   Google Scholar
• Arenillas JF, Alvarez-Sabin J, Molina CA et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34(10), 2463–2468 (2003).
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Gavin CM et al An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. j Neuroimmunol 139(1-2), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• ••The authors provide evidence of an earlyand sustained peripheral inflammatory response to acute ischemic stroke in patients with or without evidence of infection. The very early increase in concentrations of inflammatory markers after stroke may either be induced by stroke itself, or may indicate a pre-existing inflammatory condition in stroke patients which may contribute to the development of stroke.
   Google Scholar
• Guo Y, Jiang X, Zhou Z, Chen S, Zhao H, Li E Relationship between levels of serum C-reactive protein, leucocyte count and carotid plaque in patients with ischemic stroke. j Huazhong Univ. Sci Technolog. Med. St". 23(3), 263–265 (2003).
   Google Scholar
• Cao JJ, Thach C, Manolio TA et al. C- reactive protein, carotid intima-media thickness and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108(2), 166–170 (2003).
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. CitcuLation100(11), 1148–1150 (1999).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Berger A. The renaissance of C reactive protein. Br. Merl 322 (7277), 4–5 (2001).
   PubMedGoogle Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. j Clin. Invest. 111(12), 1805–1812 (2003). A critical point of view on the role of CRP in several disease and atherothrombosis.
   Google Scholar
• Blann AD, Ridker PM, Lip GY. Inflammation, cell adhesion molecules and stroke: tools in pathophysiology and epidemiology? Shake 33(9), 2141–2143 (2002).
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl. I Med. 336(14), 973–979 (1997). A classic paper on the role of CRP in cardiovascular risk in men.
   Google Scholar
• Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arteriosder Thmmb. Vasc. Biol. 20(4), 1047–1051 (2000).
   Google Scholar
• •CRP is a strong but nonspecific risk factor of fatal stroke in old persons. The authors do not support the idea that CRP has direct vascular effects that underlie fatal cerebrovascular disease.
   Google Scholar
• Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors and mortality in a prospective study in the elderly. Arterioscler. Thmmb. Vasc. Biol. 20(4), 1057–1060 (2000).
   Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl. I Med 347(20), 1557–1565 (2002).
   Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103(13), 1813–1818 (2001).
   PubMed Web of Science ®Google Scholar
• ••The standpoint of coinventor of thepatents on the use of inflammatory biomarkers in cardiovascular disease.
   Google Scholar
• Horowitz GL, Beckwith BA. C-reactive protein in the prediction of cardiovascular disease. N Engl. Med 343(7), 512–513 (2000).
   Google Scholar
• Chung MK, Martin DO, Sprecher D et al C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (24), 2886–2891 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Anzai T, Yoshikawa T et al Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines. Int. Camliol 88(2-3), 257–265 (2003).
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Crump C et al Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107(1), 87–92 (2003).
   PubMed Web of Science ®Google Scholar
• Zebrack JS, Anderson JL, Beddhu S et al Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency?" Am. Coll Camliol 42 (1), 57–63 (2003).
   Google Scholar
• Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CD. C-reactive protein in Type 1 diabetes and its relationship to coronary artery calcification. Diabetes Cam 25(10), 1813–1817 (2002).
   Google Scholar
• Connelly PW, Hanley AJ, Harris SB, Hegele RA, Zinman B. Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree. Int. J. Obes. Relat. Metab. Disord 27(3), 347–354 (2003).
   Google Scholar
• Freeman DJ, Norrie J, Caslake MJ et al C- reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51(5), 1596–1600 (2002).
   PubMed Web of Science ®Google Scholar
• Jager A, van Hinsbergh VW, Kostense PJ et al, von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler. Thromb. Vasc. Biol. 19(12), 3071–3078 (1999).
   Google Scholar
• Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S. Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with Type 2 diabetes mellitus. Atherosclerosis 169(2), 317–321 (2003).
   Google Scholar
• Theuma P, Fonseca VA. Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. CL117: Diab. Rep. 3(3), 248–254 (2003).
   Google Scholar
• Thorand B, Lowel H, Schneider A et al. C- reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch. Intern. Med 163(1), 93–99 (2003).
   Google Scholar
• Wolf M, Sandler L, Hsu K, Vossen- Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Cam 26(3), 819–824 (2003).
   PubMed Web of Science ®Google Scholar
• Shamsuzzaman AS, Winnicki M, Lanfranchi P et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Chruktion 105(21), 2462–2464 (2002).
   Google Scholar
• Teramoto S, Yamamoto H, Ouchi Y. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107(5), E40 (2003).
   Google Scholar
• Bellomo G, Lippi G, Saronio P et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. I Nephrol 16(2), 245–251 (2003).
   Google Scholar
• Chul SK, Suh JY, Kim BS et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am. j Hypertens. 16 (6), 429–433 (2003).
   PubMedGoogle Scholar
• Di Napoli M, Papa E Association between blood pressure and C-reactive protein levels in acute ischemic stroke. Hypertensio 42(6), 1117–1123 (2003).
   PubMedGoogle Scholar
• Chambers JC, Eda S, Bassett P et al C- reactive protein, insulin resistance, central obesity and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Chrulation 104(2), 145–150 (2001).
   PubMed Web of Science ®Google Scholar
• Cook DG, Mendall MA, Whincup PH et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 149(1), 139–150 (2000).
   PubMed Web of Science ®Google Scholar
• De Maat MP, Kluft C. Determinants of C- reactive protein concentration in blood. Ital. Heart 2(3), 189–195 (2001).
   PubMedGoogle Scholar
• ••A review on the physiological andpathological conditions or concomitant treatment that influence the CRP levels within the normal range in apparently healthy subjects. The concentration of CRP are associated with age, sex race, smoking, obesity consumption of coffee and alcohol, stress, physical training, lipid levels and blood pressure. Statins decrease the CRP concentration whereas estrogen increases it. With regard to most other drugs, no consistent relationship has been reported.
   Google Scholar
• Gillum RE Association of serum C-reactive protein, and indices of body fat distribution and overweight in Mexican—American children. j Natl Med. Assoc 95 (7), 545–552 (2003).
   Google Scholar
• Pieroni L, Bastard JP, Piton A, Khalil L, Hainque B, Jardel C. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab. 29(2 Pt 1), 133–138 (2003).
   Google Scholar
• Han TS, Sattar N, Williams K, Gonzalez- Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Cam 25(11), 2016–2021 (2002).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107(3), 391–397 (2003).
   Google Scholar
• Sattar N, Gaw A, Scherbakova 0 et al Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (4), 414–419 (2003) .
   Google Scholar
• Tracy RR Inflammation, the metabolic syndrome and cardiovascular risk. int. J. Clin. Pract. Suppl (134), 10–17 (2003).
   Google Scholar
• Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J. Am. Coll Carclial 38(5), 1302–1306 (2001).
   Google Scholar
• Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J. Clin. Endocrinal Metab. 88(6), 2470–2478 (2003).
   Google Scholar
• Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to total and cardiovascular mortality in older US women. Am. J. Med 114(3), 199–205 (2003).
   Google Scholar
• Wakatsuki A, Okatani Y, Fukaya T Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 107 (18), 127–128 (2003).
   PubMedGoogle Scholar
• Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch. Intern. Med 162(11), 1286–1292 (2002).
   Google Scholar
• Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 13 (5), 561–568 (2002) .
   PubMedGoogle Scholar
• Isasi CR, Deckelbaum RJ, Tracy RP, Starr TJ, Berglund L, Shea S. Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. Pediatrics 111(2), 332–338 (2003).
   PubMedGoogle Scholar
• Rothenbacher D, Hoffmeister A, Brenner H, Koenig W Physical activity, coronary heart disease and inflammatory response. Arch. Intern. Med 163(10), 1200–1205 (2003).
   Google Scholar
• Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107(3), 443–447 (2003).
   PubMedGoogle Scholar
• Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein and traditional cardiovascular risk factors in women. Arterioscler. Thmmb. Vasc. Biol. 22(10), 1668–1673 (2002).
   Google Scholar
• Brenner H, Rothenbacher D, Bode G, Marz W, Hoffmeister A, Koenig W Coronary heart disease risk reduction in a predominantly beer-drinking population. Epidemiology 12 (4), 390–395 (2001) .
   PubMedGoogle Scholar
• Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Canliol 90(12), 1279–1283 (2002).
   Google Scholar
• Steptoe A, Kunz-Ebrecht SR, Owen N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. fiychol. Med. 33(4), 667–674 (2003).
   PubMed Web of Science ®Google Scholar
• Tiemeier H, Hofman A, van Tuil HR, Kiliaan AJ, Meijer J, Breteler MM. Inflammatory proteins and depression in the elderly. Epidemiology 14(1), 103–107 (2003).
   PubMed Web of Science ®Google Scholar
• Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS. Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res. 79 (1), 49–57 (2000).
   PubMed Web of Science ®Google Scholar
• Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch. Intern Med 163(10), 1172–1179 (2003).
   PubMedGoogle Scholar
• Wehrmacher WH. Periodontal disease predicts and possibly contributes to acute myocardial infarction. Dent. Today20 (4), 80–81 (2001).
   PubMedGoogle Scholar
• De Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking. Vascul Pharmacol 39(3), 137–139 (2002).
   PubMedGoogle Scholar
• Brull DJ, Serrano N, Zito F et al. Human CRP Gene Polymorphism Influences CRP Levels. Implications for the Prediction and Pathogenesis of Coronary Heart Disease. Arterioscler. Thromb. Vasc. Biol. 23(11), 2063–2069 (2003).
   Google Scholar
• Chatha K, Anderson NR, Gama R. Ethnic variation in C-reactive protein: UK resident Indo—Asians compared with Caucasians. J. Carrliovacc. Risk9(3), 139–141 (2002).
   Google Scholar
• Hubacek JA, Stavek P, Pit'ha J, Skodova Z, Poledne R. CD14 (C-159->T) Polymorphism and levels of C-reactive protein. Cas. Lek. Cesk 142(3), 174–176 (2003).
   Google Scholar
• Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis 169(2), 279–282 (2003).
   PubMed Web of Science ®Google Scholar
• Herbeth B, Siest G, Henny J. High sensitivity C-reactive protein (CRP) reference intervals in the elderly. Clin. Chem. Lab. Med 39(11), 1169–1170 (2001).
   Google Scholar
• Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer U. Early inflammation and dementia: a 25-year follow-up of the Honolulu—Asia Aging Study. Ann. Neural 52(2), 168–174 (2002).
   Google Scholar
• Yaffe K, Lindquist K, Penninx BW et al Inflammatory markers and cognition in well-functioning African—American and white elders. Neumlogy61(1), 76–80 (2003).
   PubMed Web of Science ®Google Scholar
• Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin. Biochem. 33(8), 601–610 (2000).
   PubMedGoogle Scholar
• Danesh J, Pepys MB. C-reactive protein in healthy and in sick populations. Eur. Heart 121(19), 1564–1565 (2000).
   Google Scholar
• Ford ES, Giles WH, Myers GL, Mannino DM. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999–2000. Clin. Chem. 49(4), 686–690 (2003).
   Google Scholar
• Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46(7), 934–938 (2000).
   PubMed Web of Science ®Google Scholar
• Imhof A, Frohlich M, Loewel H et al Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin. Chem. 49(4), 669–672 (2003).
   PubMedGoogle Scholar
• Kayaba K, Ishikawa S, Gotoh T et al. Five- year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993–1998. Jpn Ciicj 64(4), 303–308 (2000).
   Google Scholar
• Primatesta P, Falaschetti E, Poulter NR. Influence of hormone replacement therapy on C-reactive protein: population-based data. J. Cardiovacc. Risk10(1), 57–60 (2003).
   Google Scholar
• Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin. Chem. 49(4), 666–669 (2003).
   PubMed Web of Science ®Google Scholar
• Chenillot 0, Henny J, Steinmetz J, Herbeth B, Wagner C, Siest G. High sensitivity C-reactive protein: biological variations and reference limits. Clin. Chem. Lab. Med 38(10), 1003–1011 (2000).
   Google Scholar
• Kluft C, De Maat MP. Determination of the habitual low blood level of C-reactive protein in individuals. Ital. Heart 2 (3), 172–180 (2001).
   PubMedGoogle Scholar
• ••An acute analysis on the intraindividualvariability of CRP levels and how to obtain the habitual level. The large intraindividual variability of CRP (approximating 30%) renders it difficult to position an individual reliably in smaller categories, such as tertiles, quartiles or quintiles of the total distribution. It is suggested that it would be most practical to have a goal of a single decision level or threshold only. A practical working scheme is also proposed.
   Google Scholar
• Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin. Chem. 49(8), 1258–1271 (2003).
   PubMed Web of Science ®Google Scholar
• ••The influence of assay precision,sensitivity, matrix effects, calibration and standardization on CRP measurements used to calculate cardiovascular risk. Since an individual's CRP concentration will be interpreted according to fixed cut-points, issues related to the preanalytic and analytic components of CRP measurement must be considered and standardized where possible to avoid potential misclassification of cardiovascular risk. Efforts to define performance criteria for high-sensitivity CRP applications coupled with growing awareness of the physiologic aspects of CRP most likely will lead to refinements in standardization, improved performance in quality-assessment schemes and enhanced risk prediction.
   Google Scholar
• Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 47(3), 444–450 (2001).
   PubMed Web of Science ®Google Scholar
• Middleton J. Effect of analytical error on the assessment of cardiac risk by the high-sensitivity C-reactive protein and lipid screening model. Clin. Chem. 48 (11), 1955–1962 (2002).
   PubMedGoogle Scholar
• Pradhan AD, Manson JE, Rossouw JE et al Inflammatory biomarkers, hormone replacement therapy and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAIVIA 288(8), 980–987 (2002).
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J. Med. 349(6), 523–534 (2003).
   Google Scholar
• Gotto AM, Jr. Statins and C-reactive protein: considering a novel marker of cardiovascular risk. Prev. Can:lid 5 (4), 200–203 (2002).
   Google Scholar
• Di Napoli M. Benefits of statins in cerebrovascular disease. Cum Opin. Investig. Drugs (2004) (In Press).
   Google Scholar
• Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med. 114(6), 485–494 (2003).
   Google Scholar
• Ess SM, Szucs TD. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ital. Heart 2(3), 181–188 (2001).
   Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3), 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa E Clinical use of C-reactive protein for prognostic stratification in ischemic stroke: has the time come for including it in the patient risk profile? Stroke 34(2), 375–376 (2003).
   Google Scholar
• Di Napoli M, Papa E Inflammation, statins and outcome after ischemic stroke. Stroke 32(10), 2446–2447 (2001).
   PubMedGoogle Scholar
• Guo Y, Jiang X, Chen S, Zhao HW, Gu KY. C-reactive protein as an important prognostic marker for ischemic stroke. Zhonghua Yu Fang Yi Xue Za Zhi. 37(2), 102–104 (2003).
   PubMedGoogle Scholar
• Di Napoli M. Early inflammatory response in ischemic stroke. Thmmb. Res. 103(3), 261–264 (2001). ill Di Napoli M, Papa F, Bocola V. Periodontal disease, C-reactive protein and ischemic stroke. Airh. Intern. Med. 161 (9), 1234–1235 (2001).
   Google Scholar
• Cha JK, Jeong MH, Lee KM et al. Changes in platelet p-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. j Thromb. Thrombolysis. 14(2), 145–150 (2002).
   PubMedGoogle Scholar
• Lalouschek W, Lang W Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stoke 34(1), 105–110 (2003).
   PubMedGoogle Scholar
• Di Napoli M, Papa E Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of c-reactive protein in patients with first-ever ischemic stroke. Stmke 34(12), 2922–2924 (2003). Concomitant treatment with angiotensin-converting enzyme inhibitor at the time of an acute stroke is associated with lower inflammatory response and better long-term outcomes, apparently apart from the effects on blood pressure.
   Google Scholar
• Di Napoli M. Editorial comment-C-reactive protein and vascular risk in stroke patients: potential use for the future. Stroke 34(10), 2468–2470 (2003).
   PubMedGoogle Scholar
• Gorelick PB, Sachar R, Smith DB et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAIVIA 281 (12), 1112–1120 (1999).
   PubMed Web of Science ®Google Scholar
• Koenig W Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int. Suppl (84), S58—S61 (2003). An interesting review paper on the role of CRP as a risk marker of cardiovascular disease. This review focuses on the importance of high-sensitivity CRP in cardiovascular risk stratification in coronary heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk through reduction in high-sensitivity CRP
   Google Scholar
• Szalai AJ. The biological functions of C-reactive protein. Vascul Pharmacol 39(3), 105–107 (2002).
   PubMedGoogle Scholar
• Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Gun. Cardiol 26(1 Suppl. 1), I11-114 (2003).
   Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital. Heard 2(3), 196–199 (2001).
   PubMedGoogle Scholar